Pay in 4 interest-free payments of $6.39 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
SURMOUNT-1 trial
Integration with EHRs and Clinical Workflow For providers, ePA for GLP-1 drugs must fit smoothly into existing workflows to be effective
Enhances overall metabolic efficiency
Regardless of the genotype or presence of status epilepticus, about 30% of patients exhibit transient, non-specific, periodic unilateral epileptic discharges during the acute phase, though these are rarely observed in the chronic phase (29)
For people with both obesity and diabetes, surgery is clearly more effective than GLP-1s for preventing deaths from cardiovascular disease, Dr
Seven additional Phase 3 TRIUMPH trials are expected to report results throughout 2026, covering obesity, type 2 diabetes, sleep apnea, chronic low back pain, and metabolic liver disease (ClinicalTrials.gov)
